Maiva Pharma, a global CMO/CDMO specializing in sterile injectables, has inaugurated a new manufacturing facility in Shoolagiri, Tamil Nadu, India. This expansion enhances capacity for vials, pre-filled syringes, cartridges, and lyophilized products, positioning the company to better serve global pharmaceutical and biotechnology partners. For overseas buyers and distributors in medical aesthetics, this signals increased supply-chain capacity for sterile injectables, which are critical for aesthetic treatments such as dermal fillers and botulinum toxins.
Facility overview
The new facility is located on a 22-acre site and is designed to meet current and future market demands. It features advanced manufacturing technologies, flexible production capabilities, and world-class quality systems. Upon full development, it will house six manufacturing lines capable of producing a broad range of sterile injectable dosage forms, including vials, pre-filled syringes (PFS), cartridges, suspension products, and lyophilized formulations.
Phase 1 expansion details
As part of Phase 1, Maiva Pharma has commissioned three dedicated manufacturing lines: a high-speed vial filling line, a combined pre-filled syringe and cartridge line, and a lyophilization line. The facility is supported by advanced Quality Control chemical laboratories and state-of-the-art Microbiology laboratories, enabling comprehensive in-house analytical testing and quality assurance.
Key technology highlight
A key feature is the use of advanced isolator-based manufacturing lines for liquid vials, pre-filled syringes, cartridges, and lyophilized vials. Isolator technology enhances sterility assurance, operational efficiency, and manufacturing flexibility, supporting production for regulated global markets. This is particularly relevant for aesthetic injectables requiring high sterility standards.
What buyers should watch
For overseas importers and distributors of aesthetic injectables, this expansion increases Maiva Pharma's capacity to produce sterile injectables, including pre-filled syringes and vials commonly used in aesthetic medicine. The facility's compliance with international regulatory standards and its focus on complex formulations may offer new sourcing opportunities for high-quality, contract-manufactured injectables.
Executive comment
Dr. Bhaskar Krishna, MD & CEO of Maiva Pharma, stated: “The inauguration of our Shoolagiri facility represents a major step in Maiva Pharma’s journey to become a globally preferred partner in sterile injectables manufacturing. With advanced manufacturing technologies, expanded capacity, and diversified delivery system capabilities, we are well-positioned to support our customers’ evolving needs and accelerate access to high-quality injectable therapies worldwide.”
Source: Read the original report | Published: June 16, 2026